402 related articles for article (PubMed ID: 27441513)
1. Update on New Therapies With Immune Checkpoint Inhibitors.
Peterson JJ; Steele-Moses SK
Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
[TBL] [Abstract][Full Text] [Related]
2. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
3. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
4. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
5. The development of immunotherapy in older adults: New treatments, new toxicities?
Helissey C; Vicier C; Champiat S
J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
[TBL] [Abstract][Full Text] [Related]
6. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].
Szekanecz É; Szekanecz Z
Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
11. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.
Keung EZ; Wargo JA
Surg Oncol Clin N Am; 2019 Jul; 28(3):369-386. PubMed ID: 31079794
[TBL] [Abstract][Full Text] [Related]
12. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
15. Understanding Immune Checkpoint Inhibitors for Effective Patient Care.
Rubin KM
Clin J Oncol Nurs; 2015 Dec; 19(6):709-17. PubMed ID: 26583635
[TBL] [Abstract][Full Text] [Related]
16. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
Romano G; Gawlinski A
Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.
Gedye C; van der Westhuizen A; John T
Intern Med J; 2015 Jul; 45(7):696-701. PubMed ID: 25444021
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
Teng F; Kong L; Meng X; Yang J; Yu J
Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
[TBL] [Abstract][Full Text] [Related]
19. [Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].
Reinmuth N; Bitzer M; Deschler-Baier B; Fischer JR; Kuon J; Leipe J; Rawluk J; Schulz C; Heußel CP; Schultheiß M
Dtsch Med Wochenschr; 2019 Mar; 144(5):346-353. PubMed ID: 30699440
[TBL] [Abstract][Full Text] [Related]
20. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
